All news

21 September 2026

Medicare's obesity-drug rollout: 700,000 seniors in, and most chose Lilly

Eli Lilly's CEO said 700,000 seniors have started GLP-1 drugs since Medicare began covering them in July, and seven in ten picked a Lilly medicine.

Two months into Medicare paying for weight-loss drugs, the first scorecard is in, and it comes from the company winning. Eli Lilly CEO Dave Ricks told CNBC on Monday that 700,000 seniors have started GLP-1 treatment since coverage began in July, and about 70% of them are on Lilly drugs.

What happened

GLP-1 drugs copy a hormone the gut releases after eating. They curb appetite and help people lose weight. Medicare, the federal health plan for about 66 million people who are 65 or older or have disabilities, now covers them through a temporary program called Bridge. Eligible patients pay a $50 monthly co-pay.

Four drugs are on offer: Lilly's injection Zepbound and its new pill Foundayo, plus Novo Nordisk's Wegovy injection and Wegovy pill. Ricks said Zepbound is doing most of the work, because doctors are starting with patients who have the most weight to lose and the most health complications.

Foundayo, he said, suits people who want something convenient and perhaps need to lose 25 to 30 pounds. It launched in April, a few months after Novo's pill, yet Ricks said one in three new patients on a GLP-1 pill is now taking it. He also praised the Centers for Medicare and Medicaid Services, the agency running Medicare, for a smooth rollout.

Why it matters

For Lilly, Medicare is a big new customer. 700,000 people is only about 1% of everyone Medicare covers, so there is plenty of room left if the program keeps growing. Ricks called the start "very encouraging" and said the market is expanding as the company had hoped.

It also shows how the race with Novo is going. Lilly is already a giant: Noorult data puts its market value at about $1.06 trillion, with $79.7 billion of revenue and $26.7 billion of net income over the last twelve months. Winning seven of every ten new Medicare patients suggests its lead is holding in a key new channel, even though Novo reached the pill market first.

One caveat: these figures come from Lilly's own CEO, not an independent tally, so the first official numbers will be worth comparing.

What to watch

  • What happens to Bridge, since it is a temporary program.
  • Whether Foundayo keeps gaining on Novo's Wegovy pill.
  • Lilly's next quarterly results, for the first hard numbers on Medicare sales.

Compare the two rivals on their Noorult pages: Eli Lilly and Novo Nordisk.

The companies in this story

Based on reporting by CNBC: Eli Lilly CEO David Ricks discusses GLP-1s and Medicare coverage. Facts, not advice.

More news